Astellas Pharma and OSI Pharmaceuticals claimed that the combined company creates an oncology platform supporting Astellas Pharmas’ stated growth strategy. OSI commercialises Tarceva (erlotinib), a cancer medication. As
Amgen’s Denosumab is a fully human monoclonal antibody in late stage clinical development that specifically targets Rank Ligand, the essential regulator of osteoclasts (the cells that break down
ThromboGenics and co-development partner BioInvent said that with the initiation of the trial they will receive a milestone payment of EUR10m from Roche under the terms of the
MP Biomedicals and Rusnano plan to jointly implement projects focused on anti-aging and increasing in life expectancy, as well as creating the infrastructure for innovations in the area
Ivax Diagnostics has posted a net loss of $0.96m for the first quarter 2010, or $0.03 per diluted share, compared $0.46m, or $0.02 per diluted share, for the
The data from its new in-vitro lung re-infection model shows that SNG001 can prevent the spread of infection from cell to cell, even after an influenza infection has
The results showed that the incidence of severe OM after 5 weeks of chemoradiation was 30% lower in the patients in the high dose treatment arm (0.1mg/kg; 17
The Urology Company was launched in the second half of 2009 to build a portfolio of approved products to market and distribute into the UK urology market. With
3SBio posted a net income of RMB26.65m, or RMB0.17 per diluted share, compared to RMB15.88m, or RMB0.11 per diluted share, for the prior year period. Income from operations
GSK said that this action supersedes the FDA’s recommendation from March 22, 2010 and reflects the agency’s assessment that the presence of porcine circovirus type 1 (PCV-1) in
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.